Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Purchased by NBC Securities Inc.

NBC Securities Inc. raised its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 109,021.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 55,652 shares of the company's stock after buying an additional 55,601 shares during the quarter. NBC Securities Inc.'s holdings in Takeda Pharmaceutical were worth $827,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of TAK. Farther Finance Advisors LLC grew its holdings in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after purchasing an additional 1,976 shares during the period. Crowley Wealth Management Inc. acquired a new position in Takeda Pharmaceutical in the 4th quarter valued at about $52,000. Cromwell Holdings LLC purchased a new stake in shares of Takeda Pharmaceutical in the 4th quarter valued at approximately $61,000. Venturi Wealth Management LLC increased its holdings in shares of Takeda Pharmaceutical by 554.7% during the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock worth $67,000 after buying an additional 4,260 shares during the last quarter. Finally, Lindbrook Capital LLC raised its position in shares of Takeda Pharmaceutical by 65.0% during the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after buying an additional 2,029 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Down 0.2%

NYSE TAK traded down $0.04 during trading on Friday, hitting $14.96. The stock had a trading volume of 825,846 shares, compared to its average volume of 1,983,370. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $47.59 billion, a PE ratio of 37.39, a PEG ratio of 0.24 and a beta of 0.26. The firm has a 50 day moving average price of $14.66 and a 200 day moving average price of $14.09. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $15.43.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The firm had revenue of $7.34 billion during the quarter, compared to analysts' expectations of $8.02 billion. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, equities research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.